Premium
5‐HT 2 Receptor Activation Differentially Modulates Linker Histone Kinetics and Histone Deacetylase Activity
Author(s) -
Flanagan Thomas Wayne,
Billac Gerald Bernard,
Nichols Charles David
Publication year - 2020
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2020.34.s1.05613
Subject(s) - chromatin , histone deacetylase , microbiology and biotechnology , chromatin remodeling , epigenetics , histone , histone h2a , chemistry , histone h3 , histone h1 , histone deacetylase 5 , acetylation , biology , biochemistry , gene
Introduction Alterations to chromatin dynamics and histone modification represent crucial processes metazoan cells employ to influence regulation and gene expression. As such, modification to the mobility of the linker histone, the chief component of chromatin compaction and higher‐order chromatin architecture, significantly impacts downstream transcriptional regulation and cellular processing. At present, the contributions of serotonergic signaling to not only heritable epigenetic modification but also higher‐order chromatin structure are a matter of intense research focus. Through both in vitro and in vivo assays, our lab has shown that serotonin 5‐HT 2A receptor agonists (psychedelics) exhibit differential efficacy and potency in their ability to prevent inflammatory pathway activation. Modulation to both overall chromatin structure and epigenetic signaling may represent a potential mechanism that psychedelics employ to promote their long‐lasting, therapeutic effects. Objectives We sought to evaluate the impact of chromatin compaction and histone acetylation on 5‐HT 2A functional selectivity in human embryonic kidney cells stably expressing the 5‐HT 2A receptor. Methods We utilized fluorescence recovery after photobleaching (FRAP) to probe the kinetics of the linker histone H1c transiently transfected into the aforementioned HEKH2A cell line. We concurrently measured histone deacetylase (HDAC) activity following exposure to numerous 5‐HT 2A agonists. Results 5‐HT itself minimally impacts H1c mobility, whereas compounds such as psilocin and the highly selective 5‐HT 2 agonist ( R )‐2,5‐dimethoxy‐4‐iodoamphetamine [( R )‐DOI] significantly slow H1c kinetics. Interestingly, these changes to linker histone mobility do not correlate with putative epigenetic regulation, as 5‐HT 2A compounds with anti‐inflammatory properties reduce histone deacetylase (HDAC) activity, whereas antagonism of the 5‐HT 2A receptor induces HDAC activity. Conclusion Together, this data illustrates that agonism of 5‐HT 2A receptors induce unique changes to chromatin architecture and HDAC activity, a conceivable mechanism psychedelics might employ to promote their potent therapeutic properties. Translationally, while HDAC inhibitors have emerged as attractive agents in cancer therapy and asthma treatment, their utility is limited by off‐target toxicity. 5‐HT 2A receptor activation represents a potentially more promising therapeutic strategy to modulate histone acetylation patterns for therapeutic effects. Support or Funding Information Support from this work was provided in part by the Eleusis Benefit Corporation and the LSU Foundation.